CIRM Funded Clinical Trials

Tumor stem cell-targeted immunotherapy for metastatic melanoma –a randomized phase 3 clinical trial.

Disease Area:
CIRM Grant:
CLIN2-08239 (Closed)
Award Value:
Trial Sponsor:
Caladrius Biosciences
Trial Stage:
Phase 3
Trial Status:
Targeted Enrollment:
4 ID:


NeoStem, which later changed its name to Caladrius BioScience, ran a Phase 3 trial targeting cancer stem cells. These cells are believed to be able to survive chemotherapy and other cancer-targeting treatments, and can cause a relapse by enabling tumors to grow and spread. This approach used the patient’s own tumor cells to create a personalized therapy, one designed to engage the patient’s own immune system and destroy the cancer. The trial was halted by Caladrius in January 2016 for business reasons.

CIRM Clinical Trial Resources

Patient Stories of Hope

CIRM Alpha Stem Cell Clinics

Patient Toolbox

Video on Stem Cell Trials

Other Resources

ISSCR Patient Website